MYLIP 抗体 (AA 65-103) (Cy5.5)
Quick Overview for MYLIP 抗体 (AA 65-103) (Cy5.5) (ABIN1421881)
抗原
See all MYLIP 抗体适用
宿主
克隆类型
标记
应用范围
-
-
抗原表位
- AA 65-103
-
交叉反应
- 人, 小鼠, 大鼠
-
纯化方法
- Purified by Protein A.
-
免疫原
- KLH conjugated synthetic peptide derived from human MYLIP
-
亚型
- IgG
-
-
-
-
应用备注
- IF(IHC-P) 1:50-200
-
限制
- 仅限研究用
-
-
-
状态
- Liquid
-
浓度
- 1 μg/μL
-
缓冲液
- Aqueous buffered solution containing 0.01M TBS ( pH 7.4) with 1 % BSA, 0.03 % Proclin300 and 50 % Glycerol.
-
储存液
- ProClin
-
注意事项
- This product contains ProClin: a POISONOUS AND HAZARDOUS SUBSTANCE, which should be handled by trained staff only.
-
储存条件
- -20 °C
-
储存方法
- Store at -20°C. Aliquot into multiple vials to avoid repeated freeze-thaw cycles.
-
有效期
- 12 months
-
-
- MYLIP (Myosin Regulatory Light Chain Interacting Protein (MYLIP))
-
别名
- MYLIP
-
背景
-
Synonyms: MIR, IDOL, E3 ubiquitin-protein ligase MYLIP, Inducible degrader of the LDL-receptor, Myosin regulatory light chain interacting protein, MYLIP, BZF1, BM-023, PP5242
Background: E3 ubiquitin-protein ligase that mediates ubiquitination and subsequent proteasomal degradation of myosin regulatory light chain (MRLC), LDLR, VLDLR and LRP8. Activity depends on E2 enzymes of the UBE2D family. Proteasomal degradation of MRLC leads to inhibit neurite outgrowth in presence of NGF by counteracting the stabilization of MRLC by saposin-like protein (CNPY2/MSAP) and reducing CNPY2-stimulated neurite outgrowth. Acts as a sterol-dependent inhibitor of cellular cholesterol uptake by mediating ubiquitination and subsequent degradation of LDLR.
-
基因ID
- 29116
-
UniProt
- Q8WY64
抗原
-